Diagnostic Medical Systems (XPAR:ALDMS) Cash Conversion Cycle: 0.00 (As of Dec. 2025)


XPAR:ALDMS Diagnostic Medical Systems XPAR:ALDMS
68 GF Score
Price €1.21
GF Value €1.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Diagnostic Medical Systems Cash Conversion Cycle?

Diagnostic Medical Systems XPAR:ALDMS -2.02% 68 Cash Conversion Cycle is 0.00 as of Dec. 2025. GuruFocus rates XPAR:ALDMS with a GF Score™ of 68/100 and a GF Value™ of €1.14 (Fairly Valued). The stock has 4 warning signs investors should review.

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Diagnostic Medical Systems's Days Sales Outstanding for the six months ended in Dec. 2025 was 0.
Diagnostic Medical Systems's Days Inventory for the six months ended in Dec. 2025 was 0.
Diagnostic Medical Systems's Days Payable for the six months ended in Dec. 2025 was 0.
Therefore, Diagnostic Medical Systems's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2025 was 0.00.


Diagnostic Medical Systems  (XPAR:ALDMS) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Diagnostic Medical Systems Cash Conversion Cycle Related Terms


Diagnostic Medical Systems Cash Conversion Cycle Historical Data

* Premium members only.

The historical data trend for Diagnostic Medical Systems's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnostic Medical Systems Cash Conversion Cycle Chart

Diagnostic Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.79 101.12 106.63 116.30 100.29

Diagnostic Medical Systems Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Dec25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 108.07 126.31 124.68 109.84 0.00

XPAR:ALDMS vs ABT, SYK, MDT: Cash Conversion Cycle Comparison

For the Medical Devices subindustry, Diagnostic Medical Systems's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diagnostic Medical Systems Cash Conversion Cycle vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Diagnostic Medical Systems's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Diagnostic Medical Systems's Cash Conversion Cycle falls into.


XPAR:ALDMS
68GF Score
Diagnostic Medical Systems XPAR:ALDMS
Cash Conversion Cycle is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnostic Medical Systems Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Diagnostic Medical Systems's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=67.83+186.2-153.74
=100.29

Diagnostic Medical Systems's Cash Conversion Cycle for the quarter that ended in Dec. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=0+0-0
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash Conversion Cycle →
What does a Cash Conversion Cycle of 0.00 mean?
Diagnostic Medical Systems (XPAR:ALDMS) has a Cash Conversion Cycle of 0.00 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Diagnostic Medical Systems and its competitors.
Is Diagnostic Medical Systems' Cash Conversion Cycle too high?
Diagnostic Medical Systems' current Cash Conversion Cycle is 0.00. Overall, Diagnostic Medical Systems has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diagnostic Medical Systems' Cash Conversion Cycle compare to ABT and SYK?
Diagnostic Medical Systems' Cash Conversion Cycle of 0.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Diagnostic Medical Systems and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostic Medical Systems's current Cash Conversion Cycle is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostic Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Diagnostic Medical Systems (XPAR:ALDMS) is currently considered Fairly Valued. The stock's GF Value™ is €1.14, compared to a current price of €1.21 — trading 6.1% above its estimated fair value. The current Cash Conversion Cycle is 0.00. Diagnostic Medical Systems' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Diagnostic Medical Systems (XPAR:ALDMS), the current Cash Conversion Cycle is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnostic Medical Systems (XPAR:ALDMS) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnostic Medical Systems stock appears to be overvalued. The current stock price of €1.21 is trading 6.1% above its estimated GF Value™ of €1.14. GuruFocus considers Diagnostic Medical Systems to be Fairly Valued.

Key valuation signals for XPAR:ALDMS:

  • Cash Conversion Cycle: 0.00
  • GF Value™: €1.14 vs. price of €1.21 (6.1% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALDMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Diagnostic Medical Systems Business Description

Other Exchanges 0RIA:UKDMS1:Germany
Address 9 Avenue du Canal Philippe, Gallargues le Montueux, FRA, FR-30660
Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
68GF Score

Get the complete analysis for XPAR:ALDMS

Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.21
Price
€1.14
GF Value